Company intelligence / Profile preview
Smart Immune
Paris, Francesmart-immune.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
SMART101 is currently in Phase I/II clinical trials for patients with acute leukemia or primary immunodeficiencies in the EU and US. Patient inclusions are expected to increase rapidly in 2025.
- Therapeutic areas
- HematologyImmunologyOncology
- Modalities
- Cell therapyT-cell therapyAllogeneic T-cell therapy
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Memorial Sloan KetteringGreater Paris University Hospitals (AP-HP)CELLforCURE by SEQENS
Beyond the preview
Go deeper on Smart Immune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Smart Immune.